Cidara Therapeutics Statistics Share Statistics Cidara Therapeutics has 25.36M
shares outstanding. The number of shares has increased by 84.28%
in one year.
Shares Outstanding 25.36M Shares Change (YoY) 84.28% Shares Change (QoQ) 18.41% Owned by Institutions (%) 67.03% Shares Floating 18.25M Failed to Deliver (FTD) Shares 377 FTD / Avg. Volume 0.05%
Short Selling Information The latest short interest is 2.08M, so 8.21% of the outstanding
shares have been sold short.
Short Interest 2.08M Short % of Shares Out 8.21% Short % of Float 8.22% Short Ratio (days to cover) 4.67
Valuation Ratios The PE ratio is -1.01 and the forward
PE ratio is -8.37.
Cidara Therapeutics's PEG ratio is
0.
PE Ratio -1.01 Forward PE -8.37 PS Ratio 133.87 Forward PS 427.2 PB Ratio 1.05 P/FCF Ratio -0.97 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cidara Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 4.25,
with a Debt / Equity ratio of 0.02.
Current Ratio 4.25 Quick Ratio 4.25 Debt / Equity 0.02 Debt / EBITDA -0.02 Debt / FCF -0.02 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $33.55K Profits Per Employee $-4.47M Employee Count 38 Asset Turnover 0.01 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 452.19% in the
last 52 weeks. The beta is 1.29, so Cidara Therapeutics's
price volatility has been higher than the market average.
Beta 1.29 52-Week Price Change 452.19% 50-Day Moving Average 59.42 200-Day Moving Average 31.47 Relative Strength Index (RSI) 51.89 Average Volume (20 Days) 781,500
Income Statement In the last 12 months, Cidara Therapeutics had revenue of 1.27M
and earned -169.83M
in profits. Earnings per share was -26.75.
Revenue 1.27M Gross Profit -83.61M Operating Income -176.1M Net Income -169.83M EBITDA -176.1M EBIT -176.1M Earnings Per Share (EPS) -26.75
Full Income Statement Balance Sheet The company has 189.82M in cash and 3.58M in
debt, giving a net cash position of 186.25M.
Cash & Cash Equivalents 189.82M Total Debt 3.58M Net Cash 186.25M Retained Earnings -611.26M Total Assets 534.33M Working Capital 499.47M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -176.53M
and capital expenditures -129K, giving a free cash flow of -176.66M.
Operating Cash Flow -176.53M Capital Expenditures -129K Free Cash Flow -176.66M FCF Per Share -27.82
Full Cash Flow Statement Margins Gross margin is -6557.49%, with operating and profit margins of -13811.92% and -13319.76%.
Gross Margin -6557.49% Operating Margin -13811.92% Pretax Margin -13356.16% Profit Margin -13319.76% EBITDA Margin -13811.92% EBIT Margin -13811.92% FCF Margin -13855.84%
Dividends & Yields CDTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for CDTX is $68,
which is 7.6% higher than the current price. The consensus rating is "Strong Buy".
Price Target $68 Price Target Difference 7.6% Analyst Consensus Strong Buy Analyst Count 7
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Apr 24, 2024. It was a
backward
split with a ratio of 1:20.
Last Split Date Apr 24, 2024 Split Type backward Split Ratio 1:20
Scores Altman Z-Score 27.45 Piotroski F-Score 1
